U.S. Markets open in 3 mins
  • S&P Futures

    4,244.75
    -1.00 (-0.02%)
     
  • Dow Futures

    34,434.00
    -28.00 (-0.08%)
     
  • Nasdaq Futures

    14,007.50
    +13.25 (+0.09%)
     
  • Russell 2000 Futures

    2,335.10
    +4.60 (+0.20%)
     
  • Crude Oil

    71.51
    +0.60 (+0.85%)
     
  • Gold

    1,850.10
    -29.50 (-1.57%)
     
  • Silver

    27.63
    -0.52 (-1.83%)
     
  • EUR/USD

    1.2129
    +0.0022 (+0.1819%)
     
  • 10-Yr Bond

    1.4700
    +0.0080 (+0.55%)
     
  • Vix

    15.98
    -0.12 (-0.75%)
     
  • GBP/USD

    1.4114
    -0.0002 (-0.0155%)
     
  • USD/JPY

    109.7990
    +0.1640 (+0.1496%)
     
  • BTC-USD

    40,590.48
    +4,605.71 (+12.80%)
     
  • CMC Crypto 200

    1,006.37
    +64.56 (+6.85%)
     
  • FTSE 100

    7,143.29
    +9.23 (+0.13%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against ChemoCentryx, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Boston, Massachusetts--(Newsfile Corp. - May 6, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of shareholders against ChemoCentryx, Inc. (NASDAQ: CCXI) and certain of its executives for securities fraud. Investors who purchased ChemoCentryx shares between November 26, 2019 and May 3, 2021, and who lost money are strongly encouraged to contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com, or to visit our website for information on the case. The deadline to seek appointment as lead plaintiff is July 6, 2021.

On May 4, 2021, the U.S. Food and Drug Administration released a "Briefing Document" concerning ChemoCentryx's drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis. To support its New Drug Application for avacopan, ChemoCentryx relied primarily upon its Phase III ADVOCATE study. In the Briefing Document, the FDA wrote that "[c]omplexities of the study design . . . raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan and its role in the management of" ANCA vasculitis. The FDA further wrote that it had "identified several areas of concern, raising uncertainty about the interpretability of the[] data and the clinical meaningfulness of these results . . . ." On this news, shares of ChemoCentryx stock fell approximately 45% in one day, after plummeting by over 60% during intraday trading on May 4, 2021.

The lawsuit was filed in the U.S. District Court for the Northern District of California. The case is captioned Homyk v. ChemoCentryx, Inc., et al., No. 3:21-cv-03343 (N.D. Cal.), and has been assigned to the Honorable Jon S. Tigar in the Ronald V. Dellums Federal Building & U.S. Courthouse, 1301 Clay Street, Oakland, CA 94612. The class period is between November 26, 2019 and May 3, 2021, inclusive. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

If you purchased or acquired ChemoCentryx shares between November 26, 2019 and May 3, 2021 and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com, or visit our website. The deadline to seek appointment as lead plaintiff is July 6, 2021.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
SOURCE: Block & Leviton LLP
www.blockleviton.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83025